抗生物質耐性の世界市場：薬剤クラス別、疾患別、流通チャネル別、地域別

世界の抗生物質耐性市場は、2025年には88億4,000万米ドルと推定され、2032年には128億6,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は5.5%で成長する見込みです。

図.抗生物質耐性の世界市場シェア（%）、2025年地域別

世界の抗生物質耐性市場は、近年著しい成長を遂げています。抗生物質は細菌感染の予防と治療に使用される医薬品です。抗生物質は細菌を殺すか、細菌の増殖を阻止します。最も一般的に使用される抗生物質には、ペニシリン、アモキシシリン、セファロスポリンなどがあります。しかし、過去数十年の間に、抗生物質耐性が世界的に公衆衛生の大きな脅威となってきています。細菌が抗生物質耐性を持つようになると、細菌が引き起こす感染症の治療に使われる薬が効かなくなります。その結果、病気は長期化し、死亡率も上昇します。様々な抗生物質クラスに対して耐性を持つ細菌株が増加しているのは、主に抗生物質の誤用や乱用が原因です。抗生物質耐性を促進するその他の要因としては、新しい抗生物質の開発の欠如、世界の多くの地域における衛生環境の欠如、海外渡航の増加などが挙げられます。適切に対処しなければ、抗生物質耐性は深刻な健康問題につながり、患者の転帰に影響を及ぼす可能性があります。

市場力学：

世界の抗生物質耐性菌市場の成長は、抗生物質耐性菌感染症の有病率の増加、新規抗生物質開発の不足、既存抗生物質の誤用・乱用、多くの新興国市場における感染管理の制限など、さまざまな要因によってもたらされます。しかし、代替治療法の開発や抗生物質の使用に関する厳しい規制が市場の成長を抑制する可能性があります。同市場は、新たな作用機序を持つ新規抗生物質の開発に注力する企業にとって好機となります。主要企業はまた、抗生物質耐性に対抗するため、ファージ療法、ワクチン、モノクローナル抗体などの代替治療アプローチを模索しています。産学間のパートナーシップは、この迫り来るヘルスケア危機に対処するための有望な手段です。

本調査の主な特徴

• 本レポートは、世界の抗生物質耐性市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模および複合年間成長率（CAGR）を提供しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリクスを解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の抗生物質耐性市場における主要企業をプロファイルしています。
• このレポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にします。
• 世界の抗生物質耐性市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の抗生物質耐性市場の分析に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 感染症の蔓延率の上昇
  • 抗生物質耐性診断の進歩
  • 増加する研究開発活動
• 主なハイライト
• 派遣会社と派遣先雇用主のためのガイドライン
• 市場動向
• PEST分析
• 投資と資金調達
• 合併、買収、および提携
• 提供される主なサービス
• トップ市場プレーヤーの特定
• 看護師の人員配置の優位性
• 国別のヘルスケア費支出

第4章 世界の抗生物質耐性市場- コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 世界の抗生物質耐性市場：薬剤クラス別、2020年～2032年

• オキサゾリジノン
• リポグリコペプチド
• テトラサイクリン
• セファロスポリン
• その他（併用療法など）

第6章 世界の抗生物質耐性市場：疾患別、2020年～2032年

• cUTI（複雑性尿路感染症）
• CDI（クロストリディオイデス・ディフィシル感染症）
• ABSSSI（急性細菌性皮膚および皮膚構造感染症）
• HABP（院内細菌性肺炎）
• CABP（市中肺炎）
• cIAI（複雑性腹腔内感染症）
• その他（BSI（血流感染症）など）

第7章 世界の抗生物質耐性市場：流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の抗生物質耐性市場：地域別、2020年～2032年

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • Melinta Therapeutics
  • Merck &Co., Inc.
  • Allergan
  • Pfizer Inc.
  • Tetraphase Pharmaceutical, Inc.
  • TeamHealth
  • Theravance Biopharma
  • WOCKHARDT
  • Entasis Threapeutics
  • Paratek Pharmaceutials, Inc.
  • Seres Therapeutics
  • Achaogen Inc.
  • Basilea Pharmaceutical Ltd.
  • Nabriva Threapeutics plc
  • NEMESIS BIOSCIENCE LTD.

第10章 セクション

• 参考文献
• 調査手法
• 出版社について

Global Antibiotic Resistance Market is estimated to be valued at USD 8.84 Bn in 2025 and is expected to reach USD 12.86 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2032.

Figure. Global Antibiotic Resistance Market Share (%), By Region 2025

The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.

Market Dynamics:

The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.

Key Features of the Study:

• This report provides an in-depth analysis of the global antibiotic resistance market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global antibiotic resistance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market

Detailed Segmentation:

• Global Antibiotic Resistance Market, By Drug Class
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Cephalosporins
  • Others (Combination therapies, etc.)
• Global Antibiotic Resistance Market, By Disease
  • cUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides difficile Infection)
  • ABSSSI (Acute bacterial skin and skin structure infections)
  • HABP (Hospital-acquired bacterial pneumonia)
  • CABP (Community-acquired pneumonia)
  • cIAI (Complicated intra-abdominal infection)
  • Others (BSI (Bloodstream infection), etc.)
• Global Antibiotic Resistance Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Antibiotic Resistance Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • Allergan
  • Pfizer Inc.
  • Tetraphase Pharmaceutical, Inc.
  • Theravance Biopharma
  • WOCKHARDT
  • Entasis Threapeutics
  • Paratek Pharmaceutials, Inc.
  • Seres Therapeutics
  • Achaogen Inc.
  • Basilea Pharmaceutical Ltd.
  • Nabriva Threapeutics plc
  • NEMESIS BIOSCIENCE LTD.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Disease
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising prevalence of infectious diseases
  • Advancement in antibiotic resistance diagnosis
  • Growing number of R&D activities
• Key Highlights
• Guidelines for the Temporary Staffing Agency & the Host Employer
• Market Trends
• PEST Analysis
• Investments and Fundings
• Mergers, Acquisitions, and Collaborations
• Key Services Offered
• Identification of Top Market Players
• Nurse Staffing Dominance
• Healthcare Spending by Country

4. Global Antibiotic Resistance Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Antibiotic Resistance Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oxazolidinones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Lipoglycopeptides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Tetracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Cephalosporins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (Combination therapies, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Antibiotic Resistance Market, By Disease, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• cUTI (Complicated Urinary Tract Infections)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• CDI (Clostridioides difficile Infection)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• ABSSSI (Acute bacterial skin and skin structure infections)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• HABP (Hospital-acquired bacterial pneumonia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• CABP (Community-acquired pneumonia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• cIAI (Complicated intra-abdominal infection)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (BSI (Bloodstream infection), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Antibiotic Resistance Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Antibiotic Resistance Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • Melinta Therapeutics
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck & Co., Inc.
  • Allergan
  • Pfizer Inc.
  • Tetraphase Pharmaceutical, Inc.
  • TeamHealth
  • Theravance Biopharma
  • WOCKHARDT
  • Entasis Threapeutics
  • Paratek Pharmaceutials, Inc.
  • Seres Therapeutics
  • Achaogen Inc.
  • Basilea Pharmaceutical Ltd.
  • Nabriva Threapeutics plc
  • NEMESIS BIOSCIENCE LTD.
• Analyst Views

10. Section

• References
• Research Methodology
• About us